Subject: Miles Seeks to License HIV Drug
Date: Published: 11/9/92 (21 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    Miles Seeks to License HIV Drug

    PITTSBURGH -- Miles Inc. said it applied for U. S. Food and Drug
 Administration approval to license Gamimune-N, an intravenous
 immunoglobulin for treating certain children infected with the human
 immunodeficiency virus.
    A study indicated that the drug reduced the viral, serious
 bacterial and minor bacterial infections in HIV-infected children.
 In 1986, the FDA approved the drug for patients suffering from
 immunesystem disorders stemming from chemotherapy, severe burns,
 primary immunodeficiency and idiopathic thromocytopenic purpura.
    Miles is a chemical, health care and imaging unit of Germany's
 Bayer AG. 

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]